How Theranos' faulty blood tests got to market – and what that shows about gaps in FDA regulation
- Written by: Ana Santos Rutschman, Assistant Professor of Law, Saint Louis University
Theranos promised that a drop of blood could yield many health secrets.
RapidEye/E+ via Getty ImagesOne of the most high-profile trials of the year is underway to decide whether Theranos founder Elizabeth Holmes defrauded patients and investors.
Her blood testing startup, once valued at almost US$10 billion, was based on a seemingly revolutionary...
